Eric Anton Hughes MD PHD
Head of R&D and CMO at Teva Pharmaceuticals
Join to View Full Profile
400 Interpace ParkwayParsippany, NJ 07054
Phone+1 609-705-5775
Dr. Hughes is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Infectious Disease, 2001 - 2004- Yale-New Haven Medical CenterResidency, Internal Medicine, 1999 - 2002
Yale School of MedicineClass of 1999
Certifications & Licensure
CT State Medical License 2002 - 2027
PA State Medical License 2005 - 2026
NJ State Medical License 2004 - 2023
Publications & Presentations
PubMed
- 3 citationsPreparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future.Stacey J Adam, Timothy G Buchman, Judith S Currier, Ruxandra Draghia-Akli, Josh P Fessel
Journal of Clinical and Translational Science. 2024-01-01 - 2 citationsOverview of ACTIV trial-specific lessons learned.Ruxandra Draghia-Akli, Sarah W Read, Eric A Hughes
Journal of Clinical and Translational Science. 2024-01-01 - 25 citationsAntiviral Activity of Narlaprevir Combined with Ritonavir and Pegylated Interferon in Chronic Hepatitis C PatientsJoep de Bruijne, J.F. Bergmann, Henk W. Reesink, Christine J. Weegink, Richard Molenkamp
Hepatology. 2010-11-01
Press Mentions
New Long-Term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS ObservedSeptember 21st, 2025- Teva Pharma Announces USFDA Filing Acceptance for Ajovy in Pediatric Episodic Migraine PreventionAugust 5th, 2025
- Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in AdultsDecember 13th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
